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Kidney function should be 
measured before coronary artery 
bypass grafting
Recent studies in the general population and in cohorts 
with previous cardiovascular diseases indicate that 
microalbuminuria and decreased kidney function are sensitive 
risk factors for future cardiovascular events. Two studies 
in a recent issue of Circulation show that the level of renal 
function has a profound eff ect on the prognosis of patients 
undergoing coronary artery bypass graft ing (CABG) surgery. 
In the fi rst study,1 Hillis et al. determined the ‘estimated’ 
glomerular fi ltration rate (eGFR) at the time of CABG in 2067 
consecutive patients. Aft er a median follow-up of 2.3 years, 
they noted that mean eGFR was signifi cantly lower in patients 
who died during follow-up than in survivors. Also, eGFR was 
an independent predictor of mortality during the follow-up 
period; for every 10 ml increase in eGFR, overall mortality 
was reduced by 20% and 30-day postoperative mortality was 
reduced by 32%. In the second study,2 Cooper et al. reviewed 
the adult database of the Society of Th oracic Surgeons from 
July 2000 through December 2003. In the approximately 
500 000 patients evaluated, 51% had stage 2 nephropathy 
(eGFR of 60–90 ml/min); 24% had stage 3 nephropathy 
(eGFR of 30–59 ml/min); and 3.5% had stage 4 or 5. Operative 
mortality increased with declining level of eGFR, rising from 
1.3% in stage 2 nephropathy to more than 9% in stages 4 and 
5. Th e authors also found that preoperative eGFR was one of 
the most powerful predictors of cardiovascular outcome. In 
an accompanying editorial,3 Sarafi dis and Bakris suggested 
that as part of the preoperative laboratory evaluation, patients 
considered for CABG surgery should have their eGFR 
measured, and that eGFR should be integrated into clinical risk 
prediction models for morbidity and mortality aft er CABG. 
(1Circulation 2006; 113: 1056–1062. 2Circulation 2006; 113: 
1063–1070. 3Circulation 2006; 113: 1046–1047)
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Functional expression of the renin–
angiotensin system in human 
podocytes
Clinical studies have demonstrated that angiotensin-
converting enzyme (ACE) inhibitors and angiotensin type 
1 (AT1) receptor blockers reduce proteinuria and retard 
progression of glomerular diseases, including diabetic 
nephropathy. Podocytes synthesize various components of the 
glomerular basement membrane and the slit diaphragm and 
are critically involved in the maintenance of the glomerular 
fi ltration barrier. Further, injury to podocytes may alter 
the foot process–slit diaphragm complex and cause loss of 
glomerular permselectivity and proteinuria. Interestingly, little 
is known about the expression and function of the renin–
angiotensin system in podocytes. In their study, Liebau et al. 
demonstrated functional expression of key components of the 
renin–angiotensin system in diff erentiated human podocytes. 
Podocytes expressed mRNA for angiotensinogen, renin, ACE 
type 1, and the AT1 and AT2 receptor subtypes. By immunoblot 
and immunostaining, expression of the AT1 and AT2 receptors 
was demonstrated both in diff erentiated human podocytes 
and in the human kidney cortex. In diff erentiated human 
podocytes, angiotensin II increased cytosolic Ca2+ via AT1 
receptors. Finally, angiotensin II was secreted by podocytes. 
Although the exact function of the renin–angiotensin system 
in these cells remains unclear, additional work is warranted 
given their critical role in glomerular function and the 
therapeutic benefi ts of inhibitors of the system in a variety of 
glomerular diseases. (Am J Physiol Renal Physiol 2006; 290: 
F710–F719)
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Kidney cells that express vascular 
endothelial growth factor
Th e role of vascular endothelial growth factor (VEGF) in 
mature blood vessels is poorly understood. But a growing 
body of observations, including the side eff ects of anti-
VEGF therapies as well as the role of soluble VEGF receptor 
1 in preeclampsia, points to an important role for VEGF 
in maintenance of stable blood vessels. VEGF is a potent 
mediator of vascular permeability, and exogenous VEGF 
promotes edema and vessel leakiness. Furthermore, VEGF has 
been shown to induce fenestrations in endothelial cells, and 
fenestrated blood vessels are found in many secretory organs, 
including the kidney. Previous observations of mRNA levels 
in the adult found that VEGF is expressed in many tissues, 
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but the cellular source was not identifi ed. Using VEGF-lacZ 
adult mice, Maharaj et al. reported that VEGF was expressed 
in a cell-specifi c manner by cells overlying fenestrated and 
sinusoidal blood vessels, including podocytes, choroid 
plexus epithelium, and hepatocytes. In the kidney, VEGF was 
robustly expressed by podocytes and, to a lesser extent, by the 
proximal convoluting tubule epithelium. Podocytes extended 
foot processes that contacted the basement membrane of the 
fenestrated glomerular endothelium, and the proximal tubules 
were also lined by a rich vascular network. Interestingly, 
the authors also found that VEGF receptor 2 in the tissues 
expressing VEGF was constitutively activated, which indicates 
that VEGF was actively signaling. Th is observation is 
consistent with the role of VEGF as an active factor in adult 
life. (Am J Pathol 2006; 168: 639–648)
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Statins: a preventive strike 
against sepsis in patients with 
cardiovascular disease?
Daniel Hackam et al. recently reported in Lancet that statin 
treatment in patients with cardiovascular disease was 
associated with reduced rates of severe and fatal sepsis.1 Th e 
researchers conducted a population-based cohort analysis 
through linked administrative databases in Ontario, Canada, 
with accrual from 1997 to 2002. Th ey identifi ed 141 487 
patients older than 65 years who had been hospitalized 
for an acute coronary syndrome, ischemic stroke, or 
revascularization, and who had survived for at least 3 months 
aft er discharge. Th irty-three percent (46 662) were prescribed 
a statin within 90 days of discharge, and 67% (94 825) were 
not. Propensity-based matching, which accounted for the 
likelihood of receiving a statin, yielded a cohort of 69 168 
patients, half of whom received a statin and half of whom did 
not. Th e incidence of sepsis was lower in patients receiving 
statins than in controls. Adjustment for demographic 
characteristics, sepsis risk factors, comorbidities, and health-
care use gave similar results. Th e protective association 
between statins and sepsis persisted in high-risk subgroups, 
including patients with diabetes mellitus, chronic renal failure, 
or a history of infections. Signifi cant reductions in severe and 
fatal sepsis were also observed. No benefi t was noted with 
non-statin lipid-lowering agents. Although lipid lowering was 
initially thought to be responsible for the benefi cial eff ects of 
statins in cardiovascular disease, more recent fi ndings have 
suggested that other eff ects of statins, such as modulation of 
cellular immunity, might contribute. In view of their strong 
eff ect on infl ammation, statins may represent a desirable 
enforcement in the battle against the increasing incidence 
and morbidity of severe sepsis and septic shock in developed 
countries. Indeed, studies in animals and observational 
reports provide evidence in support of this notion. In a 
prospective, cohort study in 361 patients with acute bacterial 
infections, previous treatment with statins was associated with 
substantially reduced rates of severe sepsis and admission to 
the intensive care unit.2 However, this study was not powered 
to detect diff erences in mortality. Additional prospective 
controlled clinical trials are needed to support this exciting 
idea. (1Lancet 2006; 367: 413–418. 2Circulation 2005; 112: 
117–124)
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